Takara Bio Report

Overview

The report highlights Takara Bio's 10.9% increase in FY2019 net sales to ¥35,841 million and its continuing development of gene therapies. The company was expanding research and manufacturing facilities to support regenerative medicine products and its CDMO business. It also reports environmental data for primary production bases and describes workforce initiatives, including diversity and work-life balance.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2019
Language: English
Pages
File size

Standards

Other

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services